Last edition
News about "Ivonescimab "
Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Clinical Trial in China
Akeso has received NMPA clinical trial clearance for AK157D1, a next-generation B7-H3-targeting ADC, paving the way for a Phase I study in patients with advanced solid tumours in China.
Ivonescimab | 24/08/2026 | By News Bureau
Ivonescimab Plus Chemotherapy Approved in China for First-Line Squamous NSCLC
Ivonescimab plus chemotherapy has been approved in China for first-line squamous NSCLC, based on the HARMONi-6 Phase 3 trial and significant overall survival benefit.
Ivonescimab | 13/08/2026 | By News Bureau | 165
Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer
Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.
Ivonescimab | 10/08/2026 | By News Bureau
Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer
Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.
Ivonescimab | 30/07/2026 | By News Bureau | 127
Akeso Secures Fifth NMPA Breakthrough Designation for Ivonescimab
The breakthrough designation supports ivonescimab combined with chemotherapy for first-line treatment of advanced Biliary Tract Cancer (BTC), based on an ongoing phase-III study comparing it with durvalumab-based chemotherapy.
Ivonescimab | 07/02/2026 | By News Bureau | 319
China Updates Ivonescimab Label After NSCLC Survival Gains
China’s drug regulator has approved a label update for Akeso’s ivonescimab, citing Phase III data showing significant improvements in progression-free and overall survival in EGFR-TKI-resistant non-small cell lung cancer patients.<br />
Ivonescimab | 07/01/2026 | By News Bureau | 542
Akeso's Ivonescimab Wins 4th Breakthrough Therapy Nod in China for TNBC
Akeso has secured its fourth Breakthrough Therapy Designation (BTD) in China for Ivonescimab, targeting first-line treatment of triple-negative breast cancer (TNBC). The ongoing Phase III HARMONi-BC1 trial is assessing its safety and efficacy in this hard-to-treat cancer type.
Ivonescimab | 03/11/2025 | By Dineshwori | 254
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy